About Alberto A. Chiappori
Pleural and Lung Cancer
Excellence in Research
Board Certified in Medical Oncology
Works for Specialty Center
As senior member of Moffitt’s Thoracic Oncology Program, Chiappori is the primary investigator in several clinical trials, including three involving pleural mesothelioma patients and treatment research.
One of those trials is exploring the use of Opdivo (nivalumab) and Cyramza (ramucirumab), a novel immunotherapy combination that has the potential to significantly change the way mesothelioma is treated.
The trial is aimed at patients whose tumors have progressed after chemotherapy.
A second mesothelioma trial is a toxicity study for patients who undergo pleurectomy and decortication surgery, along with adjuvant chemotherapy and radiation therapy.
The third clinical trial is studying the effect of the Alimta (pemetrexed) and cisplatin chemotherapy combination for patients with a low expression of the enzyme argininosuccinate synthetase 1.
Respected for His Clinical Research
Chiappori has been at Moffitt’s Thoracic Oncology Program since 2001, serving patients and authoring numerous reports in respected medical publications.
Those include Clinical Cancer Research, Journal of Clinical Oncology and Journal of Thoracic Oncology.
Chiappori received his medical degree from the Universidad Peruana Heredia in Lima, Peru.
He did his residency at Southern Illinois University School of Medicine and his fellowship at Vanderbilt University School of Medicine.
As the lead investigator of another study, he presented his findings in 2018 at the Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
He was lauded for his work that demonstrated the effectiveness of another immunotherapy combination for advanced non-small cell lung cancer.
Works Closely with Other Mesothelioma Specialists
At Moffitt, Chiappori works closely with thoracic surgeon Dr. Jacques Fontaine, director of the Mesothelioma Research and Treatment Center.
Moffitt’s program includes a wealth of experience in treating mesothelioma, the rare and aggressive cancer caused by exposure to asbestos.
Oncologists, radiologists, pathologists, surgeons and supportive-care providers meet regularly to discuss each case, providing a personalization to care that is tough to match.
The center is known for its expertise in treating all forms of mesothelioma and its multidisciplinary approach to therapy.
Disclaimer: Dr. Alberto A. Chiappori has no professional affiliation with Asbestos.com.
2 Cited Article Sources
Moffitt Cancer Center. (n.d.). Alberto A. Chiappori, MD.
Retrieved from: https://moffitt.org/providers/Alberto-Chiappori?lang=en
- Ecco-The European Cancer Organization. (2018, November 14). Combination of two immunotherapies show activity in non-small cell lung cancer patients. Retrieved from: https://www.eurekalert.org/pub_releases/2018-11/eeco-cot111318.php
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified April 8, 2019